{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:13:15Z","timestamp":1792458795425,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic lymphocytic leukemia (CLL) is a mature B cell neoplasm with a predilection for older individuals. While previous studies have identified epigenetic signatures associated with CLL, whether age-related DNA methylation changes modulate CLL relapse remains elusive. In this study, we examined the association between epigenetic age acceleration and time to CLL relapse in a publicly available dataset. DNA methylation profiling of 35 CLL patients prior to initiating chemoimmunotherapy was performed using the Infinium HumanMethylation450 BeadChip. Four epigenetic age acceleration metrics (intrinsic epigenetic age acceleration [IEAA], extrinsic epigenetic age acceleration [EEAA], PhenoAge acceleration [PhenoAA], and GrimAge acceleration [GrimAA]) were estimated from blood DNA methylation levels. Linear, quantile, and logistic regression and receiver operating characteristic curve analyses were conducted to assess the association between each epigenetic age metric and time to CLL relapse. EEAA (<jats:italic>p<\/jats:italic>\u2009=\u20090.011) and PhenoAA (<jats:italic>p<\/jats:italic>\u2009=\u20090.046) were negatively and GrimAA (<jats:italic>p<\/jats:italic>\u2009=\u20090.040) was positively associated with time to CLL relapse. Simultaneous assessment of EEAA and GrimAA in male patients distinguished patients who relapsed early from patients who relapsed later (<jats:italic>p<\/jats:italic>\u2009=\u20090.039). No associations were observed with IEAA. These findings suggest epigenetic age acceleration prior to chemoimmunotherapy initiation is associated with time to CLL relapse. Our results provide novel insight into the association between age-related DNA methylation changes and CLL relapse and may serve has biomarkers for treatment relapse, and potentially, treatment selection.<\/jats:p>","DOI":"10.1186\/s13148-023-01496-8","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T10:40:28Z","timestamp":1683715228000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Time to relapse in chronic lymphocytic leukemia and DNA-methylation-based biological age"],"prefix":"10.1186","volume":"15","author":[{"given":"Drew R.","family":"Nannini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Egwom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthilnathan","family":"Palaniyandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard C.","family":"Hildebrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"issue":"9","key":"1496_CR1","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.3324\/haematol.2019.236000","volume":"105","author":"J Delgado","year":"2020","unstructured":"Delgado J, Nadeu F, Colomer D, Campo E. Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. Haematologica. 2020;105(9):2205\u201317. https:\/\/doi.org\/10.3324\/haematol.2019.236000.","journal-title":"Haematologica"},{"key":"1496_CR2","doi-asserted-by":"publisher","first-page":"840616","DOI":"10.3389\/fonc.2022.840616","volume":"12","author":"Y Ou","year":"2022","unstructured":"Ou Y, Long Y, Ji L, et al. Trends in disease burden of chronic lymphocytic leukemia at the global, regional, and national levels from 1990 to 2019, and projections until 2030: a population-based epidemiologic study. Front Oncol. 2022;12:840616. https:\/\/doi.org\/10.3389\/fonc.2022.840616.","journal-title":"Front Oncol"},{"issue":"1","key":"1496_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","volume":"32","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23\u201333. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.019.","journal-title":"Ann Oncol"},{"issue":"4","key":"1496_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10552-007-9097-2","volume":"19","author":"JF Yamamoto","year":"2008","unstructured":"Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997\u20132002. Cancer Causes Control. 2008;19(4):379\u201390. https:\/\/doi.org\/10.1007\/s10552-007-9097-2.","journal-title":"Cancer Causes Control"},{"key":"1496_CR5","unstructured":"The Surveillance Epidemiology and End Results (SEER) Program of the National Cancer Institute. Cancer stat facts: Leukemia\u2014Chronic Lymphocytic Leukemia (CLL). https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html. Accessed December 17, 2022"},{"issue":"48","key":"1496_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/jncimonographs\/lgu001","volume":"2014","author":"SL Slager","year":"2014","unstructured":"Slager SL, Benavente Y, Blair A, et al. Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia\/small lymphocytic lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014(48):41\u201351. https:\/\/doi.org\/10.1093\/jncimonographs\/lgu001.","journal-title":"J Natl Cancer Inst Monogr"},{"key":"1496_CR7","doi-asserted-by":"publisher","unstructured":"International CLLIPIwg. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(16)30029-8","DOI":"10.1016\/S1470-2045(16)30029-8"},{"issue":"29","key":"1496_CR8","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","volume":"28","author":"T Zenz","year":"2010","unstructured":"Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28(29):4473\u20139. https:\/\/doi.org\/10.1200\/JCO.2009.27.8762.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1496_CR9","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","volume":"94","author":"RN Damle","year":"1999","unstructured":"Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840\u20137.","journal-title":"Blood"},{"issue":"5","key":"1496_CR10","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1056\/NEJMra1908213","volume":"383","author":"JA Burger","year":"2020","unstructured":"Burger JA. Treatment of chronic lymphocytic leukemia. N Engl J Med. 2020;383(5):460\u201373. https:\/\/doi.org\/10.1056\/NEJMra1908213.","journal-title":"N Engl J Med"},{"issue":"3","key":"1496_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1200\/JOP.2014.002469","volume":"11","author":"TD Shanafelt","year":"2015","unstructured":"Shanafelt TD, Borah BJ, Finnes HD, et al. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. J Oncol Pract. 2015;11(3):252\u20138. https:\/\/doi.org\/10.1200\/JOP.2014.002469.","journal-title":"J Oncol Pract"},{"issue":"2","key":"1496_CR12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1200\/JCO.2016.68.2856","volume":"35","author":"Q Chen","year":"2017","unstructured":"Chen Q, Jain N, Ayer T, et al. Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States. J Clin Oncol. 2017;35(2):166\u201374. https:\/\/doi.org\/10.1200\/JCO.2016.68.2856.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1496_CR13","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nrc3130","volume":"11","author":"SB Baylin","year":"2011","unstructured":"Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11(10):726\u201334. https:\/\/doi.org\/10.1038\/nrc3130.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1496_CR14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2009-07-232868","volume":"115","author":"M Kanduri","year":"2010","unstructured":"Kanduri M, Cahill N, Goransson H, et al. Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood. 2010;115(2):296\u2013305. https:\/\/doi.org\/10.1182\/blood-2009-07-232868.","journal-title":"Blood"},{"issue":"6","key":"1496_CR15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.4161\/epi.20237","volume":"7","author":"L Pei","year":"2012","unstructured":"Pei L, Choi JH, Liu J, et al. Genome-wide DNA methylation analysis reveals novel epigenetic changes in chronic lymphocytic leukemia. Epigenetics. 2012;7(6):567\u201378. https:\/\/doi.org\/10.4161\/epi.20237.","journal-title":"Epigenetics"},{"issue":"3","key":"1496_CR16","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/leu.2014.252","volume":"29","author":"AC Queiros","year":"2015","unstructured":"Queiros AC, Villamor N, Clot G, et al. A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. Leukemia. 2015;29(3):598\u2013605. https:\/\/doi.org\/10.1038\/leu.2014.252.","journal-title":"Leukemia"},{"issue":"16","key":"1496_CR17","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/bloodadvances.2019000237","volume":"3","author":"TK Wojdacz","year":"2019","unstructured":"Wojdacz TK, Amarasinghe HE, Kadalayil L, et al. Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials. Blood Adv. 2019;3(16):2474\u201381. https:\/\/doi.org\/10.1182\/bloodadvances.2019000237.","journal-title":"Blood Adv"},{"key":"1496_CR18","doi-asserted-by":"publisher","first-page":"117727192110679","DOI":"10.1177\/11772719211067972","volume":"17","author":"C Grimm","year":"2022","unstructured":"Grimm C, Herling CD, Komnidi A, et al. Evaluation of a prognostic epigenetic classification system in chronic lymphocytic leukemia patients. Biomark Insights. 2022;17:11772719211067972. https:\/\/doi.org\/10.1177\/11772719211067972.","journal-title":"Biomark Insights"},{"issue":"8","key":"1496_CR19","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1002\/ijc.31189","volume":"142","author":"PA Dugue","year":"2018","unstructured":"Dugue PA, Bassett JK, Joo JE, et al. DNA methylation-based biological aging and cancer risk and survival: pooled analysis of seven prospective studies. Int J Cancer. 2018;142(8):1611\u20139. https:\/\/doi.org\/10.1002\/ijc.31189.","journal-title":"Int J Cancer"},{"issue":"1","key":"1496_CR20","doi-asserted-by":"publisher","first-page":"pkaa109","DOI":"10.1093\/jncics\/pkaa109","volume":"5","author":"PA Dugue","year":"2021","unstructured":"Dugue PA, Bassett JK, Wong EM, et al. Biological aging measures based on blood DNA methylation and risk of cancer: a prospective study. JNCI Cancer Spectr. 2021;5(1):pkaa109. https:\/\/doi.org\/10.1093\/jncics\/pkaa109.","journal-title":"JNCI Cancer Spectr."},{"issue":"1","key":"1496_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41537-022-00268-2","volume":"8","author":"AG Segura","year":"2022","unstructured":"Segura AG, Prohens L, Mezquida G, et al. Epigenetic clocks in relapse after a first episode of schizophrenia. Schizophrenia (Heidelb). 2022;8(1):61. https:\/\/doi.org\/10.1038\/s41537-022-00268-2.","journal-title":"Schizophrenia (Heidelb)"},{"issue":"1","key":"1496_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s13148-019-0783-1","volume":"11","author":"M Tsagiopoulou","year":"2019","unstructured":"Tsagiopoulou M, Papakonstantinou N, Moysiadis T, et al. DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy. Clin Epigenetics. 2019;11(1):177. https:\/\/doi.org\/10.1186\/s13148-019-0783-1.","journal-title":"Clin Epigenetics"},{"issue":"25","key":"1496_CR23","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745\u201360. https:\/\/doi.org\/10.1182\/blood-2017-09-806398.","journal-title":"Blood"},{"issue":"3","key":"1496_CR24","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1093\/nar\/gkv907","volume":"44","author":"Z Xu","year":"2016","unstructured":"Xu Z, Niu L, Li L, Taylor JA. ENmix: a novel background correction method for Illumina HumanMethylation450 BeadChip. Nucleic Acids Res. 2016;44(3):e20. https:\/\/doi.org\/10.1093\/nar\/gkv907.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1496_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12864-016-3426-3","volume":"18","author":"Z Xu","year":"2017","unstructured":"Xu Z, Langie SA, De Boever P, Taylor JA, Niu L. RELIC: a novel dye-bias correction method for Illumina methylation BeadChip. BMC Genomics. 2017;18(1):4. https:\/\/doi.org\/10.1186\/s12864-016-3426-3.","journal-title":"BMC Genomics"},{"issue":"10","key":"1496_CR26","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1186\/gb-2013-14-10-r115","volume":"14","author":"S Horvath","year":"2013","unstructured":"Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14(10):R115. https:\/\/doi.org\/10.1186\/gb-2013-14-10-r115.","journal-title":"Genome Biol"},{"issue":"2","key":"1496_CR27","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2012.10.016","volume":"49","author":"G Hannum","year":"2013","unstructured":"Hannum G, Guinney J, Zhao L, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol Cell. 2013;49(2):359\u201367. https:\/\/doi.org\/10.1016\/j.molcel.2012.10.016.","journal-title":"Mol Cell"},{"issue":"4","key":"1496_CR28","doi-asserted-by":"publisher","first-page":"573","DOI":"10.18632\/aging.101414","volume":"10","author":"ME Levine","year":"2018","unstructured":"Levine ME, Lu AT, Quach A, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY). 2018;10(4):573\u201391. https:\/\/doi.org\/10.18632\/aging.101414.","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"1496_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.18632\/aging.101684","volume":"11","author":"AT Lu","year":"2019","unstructured":"Lu AT, Quach A, Wilson JG, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging (Albany NY). 2019;11(2):303\u201327. https:\/\/doi.org\/10.18632\/aging.101684.","journal-title":"Aging (Albany NY)"},{"issue":"4","key":"1496_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1257\/jep.15.4.143","volume":"15","author":"R Koenker","year":"2001","unstructured":"Koenker R, Hallock KF. Quantile regression. J Econ Perspect. 2001;15(4):143\u201356. https:\/\/doi.org\/10.1257\/jep.15.4.143.","journal-title":"J Econ Perspect"},{"issue":"6","key":"1496_CR31","doi-asserted-by":"publisher","first-page":"e13366","DOI":"10.1111\/acel.13366","volume":"20","author":"D Nachun","year":"2021","unstructured":"Nachun D, Lu AT, Bick AG, et al. Clonal hematopoiesis associated with epigenetic aging and clinical outcomes. Aging Cell. 2021;20(6):e13366. https:\/\/doi.org\/10.1111\/acel.13366.","journal-title":"Aging Cell"},{"issue":"9","key":"1496_CR32","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.18632\/aging.101020","volume":"8","author":"BH Chen","year":"2016","unstructured":"Chen BH, Marioni RE, Colicino E, et al. DNA methylation-based measures of biological age: meta-analysis predicting time to death. Aging (Albany NY). 2016;8(9):1844\u201365. https:\/\/doi.org\/10.18632\/aging.101020.","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"1496_CR33","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3324\/haematol.2019.230227","volume":"106","author":"T Yahata","year":"2021","unstructured":"Yahata T, Ibrahim AA, Hirano KI, et al. Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells. Haematologica. 2021;106(2):483\u201394. https:\/\/doi.org\/10.3324\/haematol.2019.230227.","journal-title":"Haematologica"},{"issue":"2","key":"1496_CR34","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.18632\/oncotarget.13664","volume":"8","author":"D Forte","year":"2017","unstructured":"Forte D, Salvestrini V, Corradi G, et al. The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63\/PI3K\/Akt\/p21 signaling. Oncotarget. 2017;8(2):2261\u201374. https:\/\/doi.org\/10.18632\/oncotarget.13664.","journal-title":"Oncotarget"},{"issue":"9","key":"1496_CR35","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3324\/haematol.2009.007849","volume":"94","author":"SY Kristinsson","year":"2009","unstructured":"Kristinsson SY, Dickman PW, Wilson WH, Caporaso N, Bjorkholm M, Landgren O. Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973\u20132003 in Sweden. Haematologica. 2009;94(9):1259\u201365. https:\/\/doi.org\/10.3324\/haematol.2009.007849.","journal-title":"Haematologica"},{"issue":"6","key":"1496_CR36","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3324\/haematol.2013.101378","volume":"99","author":"D Catovsky","year":"2014","unstructured":"Catovsky D, Wade R, Else M. The clinical significance of patients\u2019 sex in chronic lymphocytic leukemia. Haematologica. 2014;99(6):1088\u201394. https:\/\/doi.org\/10.3324\/haematol.2013.101378.","journal-title":"Haematologica"},{"issue":"3","key":"1496_CR37","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1124\/jpet.103.054866","volume":"307","author":"V Lamba","year":"2003","unstructured":"Lamba V, Lamba J, Yasuda K, et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther. 2003;307(3):906\u201322. https:\/\/doi.org\/10.1124\/jpet.103.054866.","journal-title":"J Pharmacol Exp Ther"},{"key":"1496_CR38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fgene.2013.00024","volume":"4","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet. 2013;4:24. https:\/\/doi.org\/10.3389\/fgene.2013.00024.","journal-title":"Front Genet"},{"issue":"1","key":"1496_CR39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/00001648-199001000-00010","volume":"1","author":"KJ Rothman","year":"1990","unstructured":"Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):43\u20136.","journal-title":"Epidemiology"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-023-01496-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-023-01496-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-023-01496-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T10:40:39Z","timestamp":1683715239000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-023-01496-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1496"],"URL":"https:\/\/doi.org\/10.1186\/s13148-023-01496-8","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]},"assertion":[{"value":"14 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Review Committee at each participating institution approved the study [].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"GH has served in advisory\/consulting roles for Incyte, Morphosys, Alexion Pharmaceuticals, Karyopharm Therapeutics, Seattle Genetics, Jannsen Pharmaceuticals, Daiichy Sanchyo; has stocks\/ownership interests in Novartis, Insys Therapeutics, Abbvie, GW Pharmaceuticals, Cardinal Health, Clovis Oncology, Cellectis, CVS Health, Celgene, Bluebird Bio, Bristol-Myers Squibb\/Medarex, Crispr Therapeutics, IDEXX Laboratories, Johnson & Johnson, Pfizer, Procter & Gamble, Vertex, Bayer, Scotts-Miracle, Charlottes Web, AImmune Therapeutics Inc, Medical PPTYS TR Inc, Caretrust Reit Inc, Moderna Therapeutics; is a member of the data safety monitoring board for Papa Therapeutics LLC; and has received research funding from Takeda, Jazz Pharmaceuticals, Pharmacyclics, Incyte, AstraZeneca.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}